A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Collagen Cross-Linked N-Telopeptide (NTx), 24-Hour Urine
Test CodeNTX24
Alias/See Also
36421
CPT Codes
82523, 82570
Includes
Creatinine
CPT code 81050 may be added at an additional charge for volume measurement
CPT code 81050 may be added at an additional charge for volume measurement
Preferred Specimen
2 mL of an unpreserved 24-hour urine collected in a plastic, leak-proof urine container
Minimum Volume
1 mL
Instructions
Do not include first morning specimen; collect all subsequent voidings. The last sample collected should be the first morning specimen voided the following morning at the same time as the previous morning's first voiding. Specify 24-hour total volume on container and test requisition.
Note: If submitting a random urine, use Test Code 36167.
Note: If submitting a random urine, use Test Code 36167.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 5 days
Frozen: 30 days
Refrigerated: 5 days
Frozen: 30 days
Methodology
Chemiluminescence (CL)
Setup Schedule
Set up: Mon-Sat; Report available: Next day after receipt at the performing laboratory. Add two (2) days for transport.
Limitations
Collagen Cross-Linked N-Telopeptide is affected by diurnal variation.
Reference Range
Collagen Cross-Linked N-Telopeptide (NTx), 24-Hour Urine
Results are primarily used for monitoring the response to therapy. A value within the premenopausal reference range does not rule out osteoporosis nor the need for therapy.
Creatinine, 24-Hour Urine
Male | |
18-29 Years | 5-88 nM BCE/mM creat |
30-39 Years | 7-51 nM BCE/mM creat |
40-49 Years | 5-47 nM BCE/mM creat |
50-60 Years | 6-43 nM BCE/mM creat |
Female | |
Premenopausal | 5-79 nM BCE/mM creat |
Creatinine, 24-Hour Urine
<3 Years | Not established |
3-8 Years | 0.10-0.80 g/24 h |
9-12 Years | 0.20-1.40 g/24 h |
13-17 Years | 0.40-1.90 g/24 h |
>17 Years | 0.50-2.15 g/24 h |
Clinical Significance
NTx is useful to assess bone resorption in patients with metabolic bone disease and monitor therapy to slow or halt osteoporotic bone loss. A decline of 30% or more of NTx over a six-month period suggests effective therapy.
Performing Laboratory
Quest Diagnostics Nichols Institute |
14225 Newbrook Drive |
Chantilly, VA 20153 |
Last Updated: June 22, 2023